The FDA is up in arms about the drug stating it is the only one that shrinks the prostate gland, when in fact there are a couple other alternatives. The FDA has asked Glaxo to stop with commercials of such and stick to relaying the information about the drug without entrenching on competitive borders.
I just posted this about the Merck and generic drug that competes in this arena, and it helps with baldness too and doctors are beginning to recommend the drug for prostate cancer victims as a way of preventing a recurrence. Competition must be pretty stiff it seems as Glaxo also offers a voucher on the website for a 30 day free trial.
Both drugs are in the shrink and grow business (hair). BD
The U.S. Food and Drug Administration said a GlaxoSmithKline PLC (GSK) television advertisement for its Avodart prostate-shrinking drug last year was misleading because it overstated the drug's effectiveness.
In a warning letter to the U.K. drug giant posted on the agency's Website Thursday, the FDA said a 60-second spot titled "Planetarium" presented " misleading comparative claims and overstates the efficacy of Avodart." The drug, which had $738 million in worldwide sales last year, is approved to shrink enlarged prostates in men, and to improve associated symptoms and conditions such as urinary retention.